New drug combo takes on advanced cancers in early trial
NCT ID NCT05708950
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Participants received the drug every two weeks and had regular scans and blood tests. Because this is a small, early study, it focuses on safety and dosing rather than proving the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KVA12123 (an experimental drug) and pembrolizumab (Keytruda, an immunotherapy)
- What this could lead to
- If successful, this could point toward a new treatment option for advanced cancers that have stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial with only 40 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
UCLA Health (Santa Monica Cancer Care)
Santa Monica, California, 90404, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Can a new tracer light up hidden prostate cancer?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug shield nerves from Chemotherapy's side effects?
- Genetic test may spare patients from unnecessary thyroid surgery